Oramed Pharmaceuticals Inc. — Director's Dealing 2021

Dec 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-12-28

Reporting Person: Rabinowitz Michael (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-28	Common Stock	F	9532	$12.98	Disposed	90468	Direct

Footnotes

F1: Payment of tax liability by withholding securities incident to the vesting of the issued security.